Journal
CANCER TREATMENT REVIEWS
Volume 36, Issue 5, Pages 425-435Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2009.12.006
Keywords
Cancer; Human AP endonuclease 1; APE1; Small molecule inhibitors
Categories
Funding
- Medical Research Council [G1000252] Funding Source: Medline
Ask authors/readers for more resources
DNA base excision repair (BER) is critically involved in the processing of DNA base damage induced by alkylating agents. Pharmacological inhibition of BER (using PARP inhibitors), either alone or in combination with chemotherapy has recently shown promise in clinical trials. Human apurinic/apyrimidinic endonuclease 1(APE1) is an essential BER protein that is involved in the processing of potentially cytotoxic abasic sites that are obligatory intermediates in BER. Here we provide a summary of the basic mechanistic role of APE1 in DNA repair and redox regulation and highlight preclinical and clinical data that confirm APE1 as a valid anticancer drug target. Development of small molecule inhibitors of APE1 is an area of intense research and current evidence using APE1 inhibitors has demonstrated potentiation of cytotoxicity of alkylating agents in preclinical models implying translational applications in cancer patients. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available